Virtus Investment Advisers LLC Acquires Shares of 3,797 Stryker Corporation $SYK

Virtus Investment Advisers LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, HoldingsChannel reports. The fund bought 3,797 shares of the medical technology company’s stock, valued at approximately $1,502,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Brighton Jones LLC increased its stake in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Assetmark Inc. increased its position in Stryker by 28.4% in the 1st quarter. Assetmark Inc. now owns 1,667 shares of the medical technology company’s stock valued at $621,000 after acquiring an additional 369 shares during the period. Foundations Investment Advisors LLC increased its position in Stryker by 9.9% in the 1st quarter. Foundations Investment Advisors LLC now owns 2,162 shares of the medical technology company’s stock valued at $805,000 after acquiring an additional 195 shares during the period. Arkadios Wealth Advisors raised its stake in Stryker by 495.9% during the 1st quarter. Arkadios Wealth Advisors now owns 4,052 shares of the medical technology company’s stock valued at $1,508,000 after acquiring an additional 3,372 shares during the last quarter. Finally, Natixis Advisors LLC lifted its position in Stryker by 3.9% during the 1st quarter. Natixis Advisors LLC now owns 191,989 shares of the medical technology company’s stock worth $71,468,000 after acquiring an additional 7,172 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. The trade was a 2.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,118 shares of company stock valued at $185,381,932 over the last quarter. Corporate insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SYK. UBS Group set a $408.00 target price on Stryker in a report on Monday, October 13th. Royal Bank Of Canada reissued an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a research note on Friday, November 14th. Truist Financial upped their price objective on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a report on Tuesday. Finally, Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Stock Performance

Shares of SYK opened at $372.04 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a 50-day simple moving average of $369.01 and a 200-day simple moving average of $380.43. The company has a market capitalization of $142.28 billion, a PE ratio of 49.28, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.